Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 11/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875302 | 0.83 | MAOB (0.55) | MAOBMAOAACHE | |
| SCHEMBL5875466 | 0.81 | MAOB (0.50) | MAOBMAOAACHE | |
| SCHEMBL5875358 | 0.80 | KMT2A (0.55) | PARP14MAOBMAOAACHENR4A2 | |
| SCHEMBL5875474 | 0.77 | IP6K1 (0.60) | MAOBMAOAACHENR4A2 | |
| SCHEMBL3503286 | 0.74 | MAOB (0.48) | MAOBMAOAKCNH2 | |
| SCHEMBL5618440 | 0.74 | MAOB (0.43) | MAOBMAOAACHEGRM5KCNH2 | |
| SCHEMBL5617591 | 0.73 | MAOB (0.45) | MAOBMAOAACHE | |
| SCHEMBL29499002 | 0.72 | PARP14 (0.48) | PARP14 | |
| SCHEMBL7710641 | 0.71 | PARP14 (0.47) | PARP14KCNH2 | |
| SCHEMBL5875436 | 0.69 | MAOB (0.47) | MAOBMAOAGRM5NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100418954-C | 3h-quinazolin-4-one derivatives | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| EP-1572666-B1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-7087612-B2 | Amine oxidase inhibitor; therapy for Alzheimer's diseases, Parkinson's disease | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| CN-1720237-A | 3h-quinazolin-4-one derivatives | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | CN | disclosed |
| EP-1572666-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | US | disclosed |
| WO-2004054985-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | MAOB, MAOA, COMT | PARP14 718/4885MAOB 1/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.